ArticleBMC public health2014
Herpes zoster vaccine (HZV): utilization and coverage 2009 - 2013, Alberta, Canada.
Article in BMC public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2023Pooled it
- HPV Vaccine utilization, Alberta 2008/09-2013/14 School year.BMC infectious diseases · 2016Trial
- Association between vaccination prescription program and herpes zoster vaccine knowledge, intention, and coverage among residents aged ≥50 in Zhejiang Province: Repeated cross-sectional surveys.Human vaccines & immunotherapeutics · 2026Article
- Bridging the intention‒behavior gap in herpes zoster vaccination: A nationwide survey in a self-payment setting.Human vaccines & immunotherapeutics · 2026Article
- Vaccination coverage, willingness and determinants of herpes zoster vaccine among individuals aged 50 and above in Ningbo, China: A population-based cross-sectional study.Human vaccines & immunotherapeutics · 2025Article
- Evaluating the impact of the vaccination prescription program on herpes zoster vaccine coverage in Ningbo, China: An interrupted time series analysis.Human vaccines & immunotherapeutics · 2025Article
- Varicella-zoster Virus Reactivation with Severe Pneumonia Following Convalescence from Coronavirus Disease: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2025Review
- Vaccine uptake, associated factors and reasons for vaccination status among the South African elderly; findings and next steps.PloS one · 2024Article
- Unraveling Herpes Zoster Vaccine Hesitancy, Acceptance, and Its Predictors: Insights From a Scoping Review.Public health reviews · 2024Article
- Willingness to vaccinate against herpes zoster in Chinese urban population: a mixed-methods study.BMJ open · 2023Article
- Vaccine promotion strategies in community pharmacy addressing vulnerable populations: a scoping review.BMC public health · 2023Article
- Vaccinations Status against Vaccine-Preventable Diseases and Willingness to Be Vaccinated in an Italian Sample of Frail Subjects.Vaccines · 2022Article
- Low willingness to vaccinate against herpes zoster in a Chinese metropolis.Human vaccines & immunotherapeutics · 2021Article
- Herpes zoster in older adults in Ontario, 2002-2016: Investigating incidence and exploring equity.PloS one · 2021Article
- Herpes Zoster Burden in Canadian Provinces: A Narrative Review and Comparison with Quebec Provincial Data.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Review
- Zoster vaccination inequalities: A population based cohort study using linked data from the UK Clinical Practice Research Datalink.PloS one · 2018Article
- Varicella and herpes zoster vaccine development: lessons learned.Expert review of vaccines · 2017Review
- Opportunities for pharmacists in vaccinating higher-risk populations.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster vaccine (HZV) is not publicly funded in the province of Alberta, Canada. We estimated vaccine coverage among those aged 60 years or older for 2013, as well as vaccine utilization rates per hundred thousand population over the period 2009 - 2013. We explored for factors associated with HZV dispensing rates.
methodsWe used administrative data from the Alberta Pharmaceutical Information Network (PIN) database to identify unique persons for whom HZV had been dispensed from community pharmacies over 2009 - 2013. PIN data were also used to estimate the pharmacy/population ratios for rural and urban Alberta over the period. Denominators for rates were estimated using mid-year population estimates from the Alberta Health Care Insurance Plan Registry. Income quintile data were estimated from the 2006 Census of Canada. Crude, age, sex, geographic (rural vs. urban), income-quintile and year specific rates of HZV vaccine dispensing were estimated per 100,000 population. Rates were adjusted for pharmacy/population ratio. Vaccine coverage for persons aged 60 years or older was estimated using counts of all unique persons for whom the vaccine was dispensed over the period in the numerator and a 2013 mid- year population denominator.
resultsHZV dispensing rates rose annually from 2009 - 2013. Vaccine coverage was estimated to be 8.4% among persons aged 60 years or older. Rates of dispensing were highest for persons aged 60-69 years and were higher for females than males and for persons from higher compared to lower income quintiles. Dispensing rates were lower for rural than for urban residents. About 2% of vaccine was dispensed for persons aged less than 50 years.
conclusionsRates of HZV dispensing are increasing rapidly in Alberta despite a lack of public funding. A small proportion of the vaccine may be dispensed off-label.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.